Bridging Eliquis Does Not Require Therapeutic-Dose Enoxaparin
You should not use therapeutic-dose enoxaparin when bridging apixaban (Eliquis) because DOACs like apixaban do not require heparin bridging for perioperative management. The 2022 CHEST guidelines explicitly address DOAC management and make no recommendation for bridging with enoxaparin when interrupting apixaban 1.
Why Bridging Is Not Indicated for Apixaban
The concept of "bridging" applies primarily to warfarin, which has a delayed onset and offset of action requiring temporary anticoagulation with heparin products. Apixaban has:
- Rapid onset (3-4 hours to peak effect)
- Predictable pharmacokinetics
- Short half-life (approximately 12 hours)
- Rapid offset when discontinued
The perioperative management pathway for DOACs involves simple interruption and resumption—not bridging with enoxaparin 1.
Correct Perioperative Management of Apixaban
Pre-operative Interruption:
- Low-to-moderate bleed risk surgery: Stop apixaban 24-48 hours before procedure (depending on renal function)
- High bleed risk surgery: Stop apixaban 48-72 hours before procedure (depending on renal function)
- No enoxaparin bridging is administered during this interruption period 1
Post-operative Resumption:
- Low-to-moderate bleed risk: Resume apixaban approximately 24 hours after surgery when hemostasis is adequate 1
- High bleed risk: Resume apixaban 48-72 hours after surgery when hemostasis is adequate 1
- For patients at very high VTE risk during the delay, low-dose prophylactic enoxaparin (40 mg daily or dalteparin 5,000 IU daily) may be considered—not therapeutic dosing 1
Critical Distinction: Prophylactic vs Therapeutic Dosing
If any enoxaparin is used post-operatively in high-risk patients awaiting apixaban resumption:
- Use prophylactic doses only: enoxaparin 40 mg subcutaneously once daily
- Never use therapeutic doses: enoxaparin 1 mg/kg twice daily or 1.5 mg/kg daily
- This is VTE prophylaxis during a brief delay, not anticoagulation bridging 1
Pharmacodynamic Considerations
Research demonstrates that co-administration of apixaban and enoxaparin produces additive anti-Xa effects, with peak anti-Xa activity 42% higher when given concomitantly 2. This additive effect:
- Increases bleeding risk without improving efficacy
- Is mitigated by separating doses by 6-12 hours when transitioning
- Supports the guideline recommendation against overlapping therapeutic anticoagulation
Common Pitfall to Avoid
Do not apply warfarin bridging protocols to apixaban. The BRIDGE trial and traditional bridging literature apply to vitamin K antagonists, not DOACs 1. Inappropriately using therapeutic-dose enoxaparin with apixaban:
- Increases major bleeding risk substantially
- Provides no thrombotic benefit
- Contradicts current evidence-based guidelines
When Enoxaparin IS Used Therapeutically
The only scenario where therapeutic-dose enoxaparin appears in apixaban trials is for initial treatment of acute VTE, where the AMPLIFY trial compared apixaban to enoxaparin 1 mg/kg twice daily followed by warfarin 3. This is treatment of active thrombosis, not perioperative bridging.